Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now? Myo Htut T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 21 January 2019 Pages: 1 - 10
The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders Jennifer CrombiePhilippe Armand T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 27 February 2019 Pages: 11 - 21
Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective? Bronwen E. Shaw Stem Cell Transplantation (R Maziarz, Section Editor) 14 January 2019 Pages: 22 - 30
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials? Sarah A. HolsteinVera J. SumanPhilip L. McCarthy Stem Cell Transplantation (R Maziarz, Section Editor) 19 January 2019 Pages: 31 - 38
Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter? Shalin KothariJens HillengassSarah A. Holstein Stem Cell Transplantation (R Maziarz, Section Editor) 22 January 2019 Pages: 39 - 46
Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy Stacie IttershagenSolveig EricsonDavid Lebwohl Stem Cell Transplantation (R Maziarz, Section Editor) 21 January 2019 Pages: 47 - 55
Treatment-Free Remission in CML: the US Perspective Guru Subramanian Guru MurthyEhab Atallah Chronic Myeloid Leukemias (M Mauro, Section Editor) 15 January 2019 Pages: 56 - 61
Correction to: Strategies for Predicting Response to Checkpoint Inhibitors Roberta ZappasodiJedd D. WolchokTaha Merghoub Correction 08 November 2018 Pages: 62 - 62
